Results 101 to 110 of about 11,301 (165)

Naturally Occurring PCSK9 Inhibitors: An Updated Review. [PDF]

Molecules
Huh J, Kim H.
europepmc   +1 more source

Differential effects of PCSK9 inhibitors and statins on plasma ceramides in coronary artery disease. [PDF]

Front Pharmacol
Zhang L, Ding Y, Zeng Y.
europepmc   +1 more source

Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective. [PDF]

Front Pharmacol
Hu D, Deng X, Feng M, Zhang X, He Q, Wang T, Feng Z.   +6 more
europepmc   +1 more source

PCSK9 inhibitors and aging: Does chronological age matter? [PDF]

Atherosclerosis
Mouslmani MA, Nouri A, Damluji AA, Nanna MG.   +3 more
europepmc   +1 more source

PCSK9 inhibitors: Going forward and beyond [PDF]

European Journal of Preventive Cardiology, 2020
openaire   +2 more sources

Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial. [PDF]

Sci Rep
Jing A, Wang J, Zhang M, Liang Y, Liu J, Zhang N, Wang J, Li X, Li C, Cui Z, Liu Y, Gao J.   +11 more
europepmc   +1 more source

Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. [PDF]

BMC Nephrol
Tang H, Li X, Wang F, Liu H, Zhang X, Liu B, Wang B.   +6 more
europepmc   +1 more source

Access to PCSK9 Inhibitors

Reviews in Cardiovascular Medicine, 2018
Jennifer G. Robinson, Norman E. Lepor, Seth J. Baum   +2 more
openaire   +1 more source

When PCSK9 Inhibitors Don't Save the Day. [PDF]

JACC Case Rep
Soffer DE.
europepmc   +1 more source

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.   +8 more
europepmc   +1 more source